Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

Having demonstrated a 76% response rate with deep and durable responses, Loxo Oncology Inc. revealed impressive pivotal data for larotrectinib, which seems poised for approval next year; the challenge now lies in awareness and adoption of testing that's required to identify the TRK fusion abnormality the drug targets.

"Testing is the key question," Loxo Chief Business Officer Jacob Van Naarden told Scrip June 3 in an interview at the American Society of Clinical Oncology meeting in Chicago, where...